Related Experiment Videos
Locally advanced head and neck cancer
M S Kies1, C L Bennett, E E Vokes
1Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0800, Houston, Texas, 77030, USA.
Current Treatment Options in Oncology
|June 12, 2002
Summary
Concurrent chemotherapy and radiation therapy significantly improves outcomes for advanced head and neck squamous cell carcinomas. Combined treatments enhance local tumor control and survival compared to radiation alone, while preserving organs and quality of life.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Advanced squamous cell carcinomas of the head and neck present significant treatment challenges.
- Radiotherapy alone has limitations in achieving optimal local tumor control and survival rates.
- Multimodal treatment strategies are increasingly explored for head and neck cancers.
Purpose of the Study:
- To evaluate the impact of simultaneous chemotherapy and radiation on advanced head and neck squamous cell carcinomas.
- To compare the efficacy of combined treatment versus radiotherapy alone.
- To assess ancillary benefits of multimodal therapy, including organ preservation and quality of life.
Main Methods:
- Review of recent clinical trials comparing combined chemoradiation with radiotherapy alone.
- Analysis of data on local tumor control, overall survival, organ preservation, and quality of life.
- Identification of high-risk patient groups for metachronous primary cancers.
Main Results:
- Combined chemotherapy and radiation demonstrates superiority over radiotherapy alone for local tumor control.
- Simultaneous administration significantly improves overall survival rates in advanced head and neck squamous cell carcinomas.
- Multimodal treatment offers benefits in organ preservation, improved cosmesis, and enhanced quality of life.
Conclusions:
- Concurrent chemoradiation is a highly effective approach for advanced head and neck squamous cell carcinomas.
- Combined treatment regimens offer superior oncologic outcomes and functional benefits.
- Future research should focus on reducing the risk of secondary cancers in this patient population.